Literature DB >> 30441107

Anti-Windup and Disturbance Rejection Controller Design of an Automated Oxygen Control System for Premature Infants.

Xuefeng Hou, Akram Faqeeh, Tyler Shinn, Roger Fales.   

Abstract

For premature infants, the peripheral oxygen saturation (SpO2) level has significant effects on their health. Manual control of the fraction of inspired oxygen (FiO2) by nursing staff is not only a highly labor intensive solution, but also a hard task to maintain infants' SpO2 within the safe range. For this clinical need, an automated oxygen control system for premature infants is developed, which is based on PI control and derivative feedback (DF) control. Clinical tests showed that, when there is either a manual-automatic mode switch and tube feeding, integral windup may occur which will lead to the degradation of control performance. To overcome this problem, an anti-windup control strategy is developed. Due to blood oxygen desaturations caused by unknown disturbances, a disturbance observer is adopted with the disturbance estimate used for disturbance rejection. According to the results of dynamic simulations, the controller with anti-windup and disturbance rejection design has the best performance among all controllers, it could achieve bumpless transfer during mode switching, decrease FiO2 in a timely manner when feeding is finished, and can shorten the recovery time from desaturation events and after feeding. This controller could minimize the time that SpO2 is outside the safe range, which is promising for clinical application.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30441107     DOI: 10.1109/EMBC.2018.8512995

Source DB:  PubMed          Journal:  Annu Int Conf IEEE Eng Med Biol Soc        ISSN: 2375-7477


  1 in total

1.  Clinical Evaluation of an Automatic Oxygen Control System for Premature Infants Receiving High-Flow Nasal Cannula for Respiratory Support: A Pilot Study.

Authors:  Xuefeng Hou; Akram Faqeeh; Ramak Amjad; John Pardalos; Roger Fales
Journal:  J Med Device       Date:  2022-05-10       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.